Erythropoietin in heart failure and other cardiovascular diseases: Hematopoietic and pleiotropic effects

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 5, Issue 5, 2005, Pages 355-375

  Manolis, Antonis S ^a,b   Tzeis, Stylianos ^a   Triantafyllou, Kostas ^a   Michaelidis, John ^a   Pyrros, Ioannis ^a   Sakellaris, Nikolaos ^a   Kranidis, Athanasios ^a   Melita, Helen ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Anemia; Cardiovascular disease; Erythropoietin; Heart failure; Myoprotection

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOPTOSIS INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMYLATED ERYTHROPOIETIN; CARDIOVASCULAR AGENT; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRITIN; FERROUS GLUCONATE; FOLIC ACID; HEMOGLOBIN; IRON; NEUROPROTECTIVE AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SPIRONOLACTONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANEMIA; BRAIN EDEMA; CARBAMOYLATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONVULSION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DYSPNEA; EXERCISE; FATIGUE; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEMATOPOIESIS; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; KIDNEY FUNCTION; LUNG EMBOLISM; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PROTEIN EXPRESSION; PURE RED CELL ANEMIA; QUALITY OF LIFE; REVIEW; SEIZURE; STROKE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; CARDIOVASCULAR DISEASES; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEART FAILURE, CONGESTIVE; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 27744573575     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800605774370326     Document Type: Review

References (180)

1. Locatelli, F., Pisoni, R.L., Combe, C., Bommer, J., Andreucci, V.E., Piera, L., Greenwood, R., Feldman, H.I., Port, F.K., Held, P.J. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant., 2004, 19, 121-132.
2. Coats, A.J.S. Anaemia and heart failure. Heart, 2004, 90, 977-979.
3. Anand, I., McMurray, J.J., Whitmore, J., Warren, M., Pham, A., McCamish, M.A., Burton, P.B.J. Anemia and its relationship to clinical outcome in heart failure. Circulation, 2004, 110, 149-154.
4. Ezekowitz, J.A., McAlister, F.A., Armstrong, P,W. Anemia is common in heart failure and is associated with poor outcomes. Circulation, 2003, 107, 223-225.
5. Felker, G.M., Adams, K.F., Gattis, W.A., O'Connor, C.M. Anemia as a risk factor and therapeutic target in heart failure. J. Am. Coll. Cardiol., 2004, 44, 959-966.
6. Sharma, R., Francis, D.P., Pitt, B., Poole-Wilson, P.A., Coats, A.J.S., Anker, S.D. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur. Heart J., 2000, 25, 1021-1028.
7. Cromie, N., Lee, C., Struthers, A.D. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart, 2002, 87, 377-378.
8. Silverberg, D.S., Wexler, D., Blum, M., Keren, G., Sheps, D., Leibovitch, E., Brosh, D., Laniado, S., Schwartz, D., Yachnin, T., Shapira, I., Gavish, D., Baruch, R., Koifman, B., Kaplan, K., Steinbruch, S., Iaina, A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol., 2000, 35, 1737-1744.
9. Locatelli, F., Alijama, P., Barany, P., Canaud, B., Carrera, F., Eckardt, K.U., Horl, W.H., Macdougal, I.C., Macleod, A., Wiecek, A., Cameron, S. European Best Practice Guidelines Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant., 2004, 19(Suppl. 2), ii1-47.
10. Chong, Z.Z., Kang, J-Q., Maiese, K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation, 2002, 106, 2973-2979.
11. Smith, K.J., Bleyer, A.J., Little, W.C., Sane, D.C. The cardiovascular effects of erythropoietin. Cardiovasc. Res., 2003, 59, 538-548.
12. Bogoyevitch, M.A. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc. Res., 2004, 63, 208-216.
13. Parsa, C.J., Matsumoto, A., Kim, J., Riel, R.U., Pascal, L.S., Walton, G.B., Thompson, R.B., Petrofski, J.A., Annex, B.H., Stamler, J.S., Koch, W.J. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Investig., 2003, 112, 999-1007.
14. Ogilvie, M., Yu, X., Nicolas-Metral, V., Pulido, S.M., Liu, C., Ruegg, U.T., Noguchi, C.T. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J. Biol. Chem., 2000, 275 (50), 39754-39761.
15. Van der Meer, P., Voors, A.A., Lipsic, E., van Gilst, W.H., van Veldhuisen, D.J. Erythropoietin in cardiovascular diseases. Eur. Heart J., 2004, 25, 285-291.
16. Bahlmann, F., Song, R., Boehm, S.M., Mengel, M., von Wasielewski, R., Lindschau, C., Kirsch, T., de Groot, K., Laudeley, R., Niemczyk, E., Gueler, F., Menne, J., Haller, H., Fliser, D. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation, 2004, 110, 1006-1012.
17. Calvillo, L., Latini, R., Kajstura, J., Leri, A., Anversa, P., Ghezzi, P., Salio, M., Cerami, A., Brines, M. Recombinant human erythropoietin protects the myocardium from ischemia - reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. USA, 2003, 100, 4802-4806.
18. Cazzola, M., Mercuriali, F., Brugnara, C. Use of recombinant human erythropoietin outside the setting of uremia. Blood, 1997, 89(12), 4248-4267.
19. Egrie, J.C., Browne, J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transplant., 2001, 16(Suppl. 3), 3-13.
20. Miyake, T., Kung, C.K., Goldwasser, E. Purification of human erythropoietin. J. Biol. Chem., 1977, 252, 5558-5564.
21. Lin, F.K., Suggs, S., Lin, C.H., Browne, J.K., Smalling, R., Egrie, J.C., Chen, K.K., Fox, G.M., Martin, F., Stabinsky, Z., Badrawi, S.M., Lai, P-H., Goldwasser, E. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA, 1985, 82(22), 7580-7584.
22. Winearls, C.G. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol. Dial. Transplant., 1998, 13(Suppl. 2), 3-8.
23. Ng, T., Marx, G., Littlewood, T., Macdougall, I. Recombinant erythropoietin in clinical practice. Postgrad. Med. J., 2003, 79, 367-376.
24. Henry, D.H., Bowers, P., Romano, M.T., Provenzano, R. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch. Intern. Med., 2004, 164, 262-276.
25. Fiordaliso, F., Chimenti, S., Staszewsky, L., Bai, A., Carlo, E., Cuccovillo, I., Doni, M., Mengozzi, M., Tonelli, R., Ghezzi, P., Coleman, T., Brines, M., Cerami, A., Latini, R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA, 2004, 102, 2046-2051.
26. Moreno, F., Sanz-Guajardo, D., Lopez-Gomez, J.M., Jofre, R., Valderrabano, F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J. Am. Soc. Nephrol., 2000, 11, 335-342.
27. Eknoyan, G., Levin, N. Clinical practice guidelines: final guideline summaries from the work groups of the national kidney foundation-dialysis outcomes quality initiative. National Kidney Foundation: New York, 1997.
28. Beguin, Y. A risk-benefit assessment of epoetin in the management of anaemia associated with cancer. Drug Safety, 1998, 19, 269-282.
29. Adamson, J.W., Schuster, M., Allen, S., Haley, N.R. Effectiveness of recombinant human erythropoietin therapy in myelodysplastic syndromes. Acta Haematol., 1992, 87(Suppl.), 20-24.
30. Phibbs, R.H., Shannon, K.M., Mentzer, W.C. Potential for treatment of anaemia of prematurity with recombinant human erythropoietin: preliminary results. Acta Haematol., 1992, 87(Suppl.), 28-33.
31. Feagan, B.G., Wong, C.J., Kirkley, A., Johnston, D.W., Smith, F.C., Whitsitt, P., Wheeler, S.L., Lau, C.Y. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann. Intern. Med., 2000, 133, 845-854.
32. Corwin, H.L., Gettingrer, A., Pearl, R.G., Fink, M.P., Levy, M.M., Shapiro, M.J., Corwin, M.J., Colton, T. Efficacy of recombinant human erythropoietin in critically ill patients. JAMA, 2002, 288, 2827-2835.
33. Macdougall, I.C. Optimizing the use of erythropoietic agents-pharmacokinetic and pharmacodynamic considerations. Nephrol. Dial. Transplant., 2002, 17(Suppl. 5), 66-70.
34. Ramakrishnan, R., Cheung, W.K., Wacholtz, M.C., Minton, N., Jusko, W.J. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J. Clin. Pharmacol., 2004, 44, 991-1002.
35. Levy, D., Kenchaiah, S., Larson, M.G., Benjamin, E.J., Kupka, M.J., Ho, K.K., Murabito, J.M., Vasan, R.S. Long term trends in the incidence of and survival with heart failure. New Engl. J. Med., 2002, 347, 1397-1402.
36. Cleland, F.G.F., Cohen-Solal, A., Aguillar, J.C., Dietz, R., Eastaugh, J., Follath, F., Freemantle, N., Gavazzi, A., van Gilst, W.H., Hobbs, F.D., Korewicki, J., Madeira, H.C., Preda, I., Swedberg, K., Widimsky, J. Management of heart failure in primary care (The IMPROVEMENT of heart failure programme): An international survey. Lancet, 2002, 360, 1631-1639.
37. Tang, W.H.W., Miller, H., Partin, M., Harris, C.M., Young, J.B. Anemia in ambulatory patients with chronic heart failure: A single-center clinical experience derived from electronic medical records. J. Am. Coll. Cardiol., 2003, 4(Suppl.), 157A.
38. Silverberg, D.S., Wexler, D., Blum, M., Schwartz, D., Wollman, Y., Iaina, A. Erythropoietin should be part of congestive heart failure management. Kidney Int., 2003, 64(Suppl. 87), S40-S47.
39. Al-Ahmad, A., Rand, W.M., Manjunath, G., Konstam, M.A., Salem, D.N., Levey, A.S., Sarnak, M.J. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol., 2001, 38, 955-962.
40. Horwich, T.B., Fonarow, G.C., Hamilton, M.A., MacLellan, W.R., Borenstein, J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J. Am. Coll. Cardiol., 2002, 39, 1780-1786.
41. McClellan, W.M., Flanders, W.D., Langston, R.D., Jurkovitz, C., Presley, R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population based study. J. Am. Soc. Nephrol., 2002, 13, 1928-1936.
42. Anand, I., McMurray, J.J., Whitmore, J., Warren, M., Pham, A., McCamish, M.A., Burton, P.B.J. Anemia and its relationship to clinical outcome in heart failure. Circulation, 2004, 110, 149-154.
43. Okonko, D.O., Anker, S.D. Anemia in chronic heart failure: Pathogenetic mechanisms. J. Card. Fail., 2004, 10(1 Suppl.), S5-S9.
44. Kosiborod, M., Smith, G.L., Radford, M.J., Foody, J.M., Krumholz, H.M. The prognostic importance of anemia in patients with heart failure. Am. J. Med., 2003, 114, 112-119.
45. Volpe, M., Tritto, C., Testa, U., Rao M.A., Martucci, R., Mirante, A., Enea, I., Russo, R., Rubattu S., Condorelli, G.L. Blood levels of Erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am. J. Cardiol., 1994, 74, 468-473.
46. Kumagai, J., Yorioka, N., Kawanishi, H., Moriishi, M., Komiya, Y., Asakimori, Y., Takahashi, N., Tsuchiya, S. Relationship between erythropoietin and chronic heart failure in patients on chronic hemodialysis. J. Am. Soc. Nephrol., 1999, 10, 2407-2411.
47. Van der Meer, P., Voors, A.A., Lipsic, E., Smilde, T.D.J., van Gilst, W.H., van Veldhuisen, D.J. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J. Am. Coll. Cardiol., 2004, 44, 63-67.
48. Jurkovitz, C.T., Abramson, J.L., Vaccarino, L.V., Weintraub, W.S., McClellan, W.M. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J. Am. Soc. Nephrol., 2003, 14, 2919-2925.
49. Harnett, J.D., Kent, G.M., Barre, P.E., Taylor, R., Parfrey, P.S. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J. Am. Soc. Nephrol., 1994, 4, 1486-1490.
50. McMahon, L.P., Roger, S.D., Levin, A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J. Am. Soc. Nephrol. 2004, 15, 1640-1647.
51. Rigatto, C., Foley, R., Jeffery, J., Negrijn, C., Tribula, C., Parfrey, P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J. Am. Soc. Nephrol., 2003, 14, 462-468.
52. Gilbertson, D., Li, S., Murray, A.M. Competing risks of death vs ESRD in Medicare beneficiaries age 65+ with chronic kidney disease, CHF, and anemia. J. Am. Soc. Nephrol., 2002, 13 (Suppl.), A848.
53. Weiss, G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev., 2002, 16, 87-96.
54. Means, R.T. Advances in the anemia of chronic disease. Int. J. Hematol., 1999, 70, 7-12.
55. Torre-Amione, G., Bozkurt, B., Deswal, A., Mann, D.L. An overview of tumor necrosis factor alpha and the failing human heart. Curr. Opin. Cardiol., 1999, 14, 206-210.
56. Sharma, R., Anker, S.D. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int. J. Cardiol., 2002, 85, 161-71.
57. Bolger, A.P., Doehner, W., Sharma, R., Coats, A.J., Anker, S. Anaemia in chronic heart failure: the relationship to inflammatory cytokine expression and prognostic importance. Circulation, 2002, 106 (Suppl.), 570-571.
58. Iversen, P.O., Woldbaek, P.R., Tonnessen, T., Christensen, G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2002, 282, R166-R172.
59. Vaziri, N.D. Erythropoietin and transferrin metabolism in nephritic syndrome. Am. J. Kidney Dis., 2001, 38, 1-8.
60. Kalra, P.R., Anagnostopoulos, C., Bolger, A.P., Coats, A.J., Anker, S.D. The regulation and measurement of plasma volume in heart failure. J. Am. Coll. Cardiol., 2002, 39, 1901-1908.
61. Anand, I.S., Chandrashekhar, Y., Ferrari, R., Poole-Wilson, P.A., Harris, P.C. Pathogenesis of oedema in chronic anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br. Heart J., 1993, 70, 357-362.
62. Androne, A.S., Katz, S.D., Lund, L., La Manca, J., Hudaihed, A., Hryniewicz, K., Mancini, D.M. Hemodilution is common in patients with advanced heart failure. Circulation, 2003, 107, 226-229.
63. Mancini, D.M., Katz, S.D., Lang, C.C., LaManca, J., Hudaihed, A., Androne, A-S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation, 2003, 107, 294-299.
64. Macdougall, I.C. The role of ACE inhibitors and angiotensin II receptor blockers in the response to erythropoietin. Nephrol. Dial. Transplant., 1999, 14, 1836-1841.
65. Albitar, S., Genin, R., Fen-Chong, M., Serveaux, M-O., Bourgeon, B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol. Dial. Transplant., 1998, 13, 1206-1210.
66. Chatterjee, B., Nydegger, U.E., Mohacsi, P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur. J. Heart Fail., 2000, 2, 393-398.
67. Juurlink, D.N., Mamdani, M.M., Lee, D.S., Kopp, A., Austin, P.C., Laupacis, A., Redelmeier, D.A. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med., 2004, 51, 543-551.
68. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant., 1999, 14 (Suppl. 50), 1-50.
69. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation- Dialysis Outcomes Quality Initiative. Am. J. Kidney Dis., 1997, 30 (Suppl. 3), S192-S240.
70. NKF-KuDOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am. J. Kidney Dis., 2001, 37 (Suppl. 1), S182-S238.
71. Goodnough, L.T., Monk, T.G., Andriole, G.L. Erythropoietin therapy. N. Engl. J. Med., 1997, 336, 933-938.
72. Silverberg, D.S., Wexler, D., Sheps, D., Blum, M., Keren, G., Baruch, R., Schwartz, D., Yachnin, T., Steinbruch, S., Shapira, I., Laniado, S., Iaina, A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol., 2001, 37, 1775-1780.
73. Silverberg, D.S., Wexler, D., Blum, M., Tchebiner, J.Z., Sheps, D., Keren, G., Schwartz, D., Baruch, R., Yachnin, T., Shaked, M., Schwartz, I., Steinbruch, S., Iaina, A. The effect of correction of anemia in diabetics and non-diabetics with severe resistant heart failure by subcutaneous erythropoietin and intravenous iron. Nephrol. Dial. Transplant., 2003, 18, 141-146.
74. Silverberg, D.S., Wexler, D., Blum, M., Iaina, A., Sheps, D., Keren, G., Scherhag, A., Schwartz, D. Effects of treatment with epoetin beta on outcomes in patients with anaemia and chronic heart failure. Kidney. Blood. Press. Res., 2005, 28, 41-47.
75. Besarab, A., Bolton, W.K., Browne, J.K., Egrie, J.C., Nissenson, A.R., Okamoto, D.M., Schwab, S.J., Goodkin, D.A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med., 1998, 39, 584-590.
76. Macdougall, I.C., Ritz, E. The normal hematocrit trial in dialysis patients with cardiac disease: are we any less confused about target haemoglobin. Nephrol. Dial. Transplant., 1998, 13, 3030-3033.
77. Ma, J.Z., Ebben, J., Xia, H., Collins, A.J. Hematocrit level and associated mortality in hemodialysis patients. J. Am. Soc. Nephrol., 1999, 10, 610-619.
78. Muirhead, N. A rationale for an individualized haemoglobin target. Nephrol. Dial. Transplant., 2002, 17(Suppl 6), 2-7.
79. Cazzola, M., Messinger, D., Battistel, V., Bron, D., Cimino, R., Enller-Ziegler, L., Essers, U., Greil, R., Grossi, A., Jager, G. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood, 1995, 86, 4446-4453.
80. Ludwig, H., Fritz, E., Leitgeb, C., Pecherstorfer, M., Samonigg, H., Schuster, J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood, 1994, 84, 1056-1063.
81. Kuriyama, S., Hopp, L., Yoshida, H., Hikita, M., Tomonari, H., Hashimoto, T., Sakai, O. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am. J. Hypertens., 1996, 9, 426-431.
82. Kristal, B., Shurtz-Swirski, R., Shasha, S.M., Manaster, J., Shapiro, G., Furmanov, M., Hassan, K., Weissman, I., Sela, S. Interaction between erythropoietin and peripheral polymorphonuclear leucocytes in hemodialysis patients. Nephron, 1999, 81, 406-413.
83. Rao, M., Pereira, B.J.G. Prospective trials on anemia of chronic disease: The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Kidney Int., 2003, 64 (Suppl. 87), S12-S19.
84. Mitka, M. Researchers probe anemia - heart failure link. J.A.M.A., 2003, 290, 1835-1838.
85. Cerami, A., Brines, M., Ghezzi, P., Cerami, C., Itri, L.M. Neuroprotective properties of epoetin alfa. Nephrol. Dial. Transplant., 2002, 17(Suppl. 1), 8-12.
86. Marti, H.H., Wenger, R.H., Rivas, L.A., Straumann, U., Digicaylioglu, M., Henn, V., Yonekawa, Y., Bauer, C., Gassmann, M. Erythropoietin gene expression in human, monkey and human brain. Eur. J. Neurosci., 1996, 8, 666-676.
87. Juul, S.E., Anderson, D.K., Li, Y., Christensen, R.D. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr. Res., 1998, 43, 40-49.
88. Konishi, Y., Chui, D.H., Hirose, H., Kunishita, T., Tabira, T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res., 1993, 609 (1-2), 29-35.
89. Sadamoto, Y., Igase, K., Sakanaka, M., Sato, K., Otsuka, H., Sakaki, S., Masuda, S., Sasaki R. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem. Biophys. Res. Commun., 1998, 253, 26-32.
90. Brines, M.L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N.C., Cerami, C., Itri, L.M., Cerami, A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. USA, 2000, 97, 10526-10531.
91. Erbayraktar, S., Grasso, G., Sfacteria, A., Xie, Q.W., Coleman, T., Kreilgaard, M., Torup, L., Sager, T., Erbayraktar, Z., Gokmen, N., Yilmaz, O., Ghezzi, P., Villa, P., Fratelli, M., Casagrande, S., Leist, M., Helboe, L., Gerwein, J., Christensen, S., Geist, M.A., Pedersen, L.O., Cerami-Hand, C., Wuerth, J.P., Cerami, A., Brines, M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. USA, 2003, 100, 6741-6746.
92. Bernaudin, M., Marti, H.H., Roussel, S., Divoux, D., Nouvelot, A., MacKenzie, E.T., Petit, E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow. Metab., 1999, 19 (6), 643-51.
93. Calapai, G., Marciano, M.C., Corica, F., Allegra, A., Parisi, A., Frisina, N., Caputi, A.P., Buemi, M. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur. J. Pharmacol., 2000, 401 (3), 349-356.
94. Catania, M.A., Marciano, M.C., Parisi, A., Sturiale, A., Buemi, M., Grasso, G., Squadrito, F., Caputi, A.P., Calapai, G. Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur. J. Pharmacol., 2002, 437 (3), 147-150.
95. Morishita, E., Masuda, S., Nagao, M., Yasuda, Y., Sasaki, R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience, 1997, 76, 105-116.
96. Lewczuk, P., Hasselblatt, M., Kamrowski-Kruck, H., Heyer, A., Unzicker, C., Siren, A.L., Ehrenreich, H. Survival of hippocampal neurons in culture upon hypoxia: effect of erythropoietin. Neuroreport, 2000, 11, 3485-3488.
97. Sakanaka, M., Wen, T.C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., Sasaki, R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. USA, 1998, 95, 4635-4640.
98. Sirén, A.L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., Mennini, T., Heumann, R., Cerami, A., Ehrenreich, H., Ghezzi, P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. USA, 2001, 98 (7), 4044-4049.
99. Bianchi, R., Buyukakilli, B., Brines, M., Savino, C., Cavaletti, G., Oggioni, N., Lauria, G., Borgna, M., Lombardi, R., Cimen, C., Comelekoglu, U., Kanik, A., Tataroglu, C., Cerami, A., Ghezzi, P. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl. Acad. Sci. USA, 2004, 101, 823-828.
100. Yoshimura, A., Misawa, H. Physiology and function of the erythropoietin receptor. Curr. Opin. Hematol., 1998, 5, 171-176.
101. Kawakami, M., Sekiguchi, M., Sato, K., Kozaki, S., Takahashi, M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem., 2001, 276, 39469-39475.
102. Digicaylioglu, M., Lipton, S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature, 2001, 412, 641-647.
103. Celik, M., Gokmen, N., Erbayraktar, S., Akhisaroglu, M., Konakc, S., Ulukus, C., Genc, S., Genc, K., Sagiroglu, E., Cerami, A., Brines, M. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. USA, 2002, 99, 2258-2263.
104. Grasso, G., Buemi, M., Alafaci, C., Sfacteria, A., Passalacqua, M., Sturiale, A., Calapai, G., De Vico, G., Piedimonte, G., Salpietro, F.M., Tomasello, F. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc. Natl. Acad. Sci. USA, 2002; 99, 5627-5631.
105. Squadrito, F., Altavilla, D., Squadrito, G., Campo, G.M., Arlotta, M., Quartarone, C., Saitta, A., Caputi, A.P. Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br. J. Pharmacol, 1999, 127, 482-488.
106. Chong, Z.Z., Kang, J.Q., Maiese, K. Angiogenesis and plasticity: role of erythropoietin in vascular systems. J. Hematother. Stem. Cell. Res., 2002, 11, 863-871.
107. Chong, Z.Z., Kang, J.Q., Maiese, K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J. Cereb. Blood Flow. Metab., 2003, 23, 320-330.
108. Maiese, K., Li, F., Chong, Z.Z. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol. Sci., 2004, 25, 577-583.
109. Agnello, D., Bigini, P., Villa, P., Mennini, T., Cerami, A., Brines, M.L., Ghezzi, P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res., 2002, 952, 128-134.
110. Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., Viviani, B., Marinovich, M., Cerami, A., Coleman, T.R., Brines, M., Ghezzi, P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med., 2003, 198, 971-975.
111. Shingo, T., Sorokan, S.T., Shimazaki, T., Weiss, S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J. Neurosci., 2001, 21, 9733-9743.
112. Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.H., Breiter, N., Jacob, S., Knerlich, F., Bohn, M., Poser, W., Ruther, E., Kochen, M., Gefeller, O., Gleiter, C., Wessel, T.C., De Ryck, M., Itri, L., Prange, H., Cerami, A., Brines, M., Siren, A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med., 2002, 8, 495-505.
113. Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., Kallunki, P., Larsen, A.K., Helboe, L., Christensen, S., Pedersen, L.O., Nielsen, M., Torup, L., Sager, T., Sfacteria, A., Erbayraktar, S., Erbayraktar, Z., Gokmen, N., Yilmaz, O., Cerami-Hand, C., Xie, Q.W., Coleman, T., Cerami, A., Brines, M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science, 2004, 305 (5681), 239-242.
114. Anagnostou, A., Liu, Z., Steiner, M., Chin, K., Lee, E.S., Kessimian, N., Noguchi, C.T. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA, 1994, 91, 3974-3978.
115. Anagnostou, A., Lee, E.S., Kessimian, N., Levinson, R., Steiner, M., Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA, 1990, 87, 5978-5982.
116. Parsa, C.J., Kim, J., Riel, R.U., Pascal, L.S., Thompson, R.B., Petrofski, J.A., Matsumoto, A., Stamler, J.S., Koch, W.J. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J. Biol. Chem., 2004, 279 (20), 20655-20662.
117. Juul, S.E., Yachnis, A.T., Christensen, R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev., 1998, 52, 235-249.
118. van der Meer, P., Lipsic, E., Henning, R.H., de Boer, R.A., Suurmeijer, A.J., van Veldhuisen, D.J., van Gilst, W.H. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur. J. Heart Fail., 2004, 6 (7), 853-859.
119. Tramontano, A.F., Muniyappa, R., Black, A.D., Blendea, M.C., Cohen, I., Deng, L., Sowers, J.R., Cutaia, M.V., El-Sherif, N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun., 2003, 308 (4), 990-994.
120. Cai, Z., Semenza, G.L. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation, 2004, 109 (17), 2050-2053.
121. Cai, Z., Manalo, D.J., Wei, G., Rodriguez, E.R., Fox-Talbot, K., Lu, H., Zweier, J.L., Semenza, G.L. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation, 2003, 108, 79-85.
122. Moon, C., Krawczyk, M., Ahn, D., Ahmet, I., Paik, D., Lakatta, E.G., Talan, M.I. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. USA, 2003, 100 (20), 11612-11617.
123. Lipsic, E., van der Meer, P., Henning, R.H., Suurmeijer, A.J., Boddeus, K.M., van Veldhuisen, D.J., van Gilst, W.H., Schoemaker, R.G. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol., 2004, 44 (4), 473-479.
124. Datta, S.R., Brunet, A., Greenberg, M.E. Cellular survival: a play in three Akts. Genes Dev., 1999, 13, 2905-2927.
125. Rafiee, P., Shi, Y., Su, J., Pritchard, K.A.Jr., Tweddell, J.S., Baker, J.E. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res. Cardiol., 2004. (Epub ahead of print).
126. Xuan, Y.T., Guo, Y., Han, H., Zhu, Y., Bolli, R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc. Natl. Acad. Sci. USA, 2001, 98, 9050-9055.
127. Shi, Y., Rafiee, P., Su, J., Pritchard, K.A.Jr., Tweddell, J.S., Baker, J.E. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res. Cardiol., 2004, 99 (3), 173-182.
128. Matsushita, H., Morishita, R., Nata, T., Aoki, M., Nakagami, H., Taniyama, Y., Yamamoto, K., Higaki, J., Yasufumi, K., Ogihara, T. Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-mediated bcl-2 suppression: in vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ. Res., 2000, 86, 974-981.
129. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997, 275, 964-967.
130. Ribatti, D., Presta, M., Vacca, A., Ria, R., Giuliani, R., Dell'Era, P., Nico, B., Roncali, L., Dammacco, F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood, 1999, 93 (8), 2627-2636.
131. Jaquet, K., Krause, K., Tawakol-Khodai, M., Geidel, S., Kuck, K.H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res., 2002, 64 (2), 326-333.
132. Dimmeler, S., Zeiher, A.M. Akt takes center stage in angiogenesis signaling. Circ. Res., 2000, 86, 4-5.
133. Shiojima, I., Walsh, K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res., 2002, 90, 1243-1250.
134. Heeschen, C., Aicher, A., Lehmann, R., Fichtlscherer, S., Vasa, M., Urbich, C., Mildner-Rihm, C., Martin, H., Zeiher, A.M., Dimmeler, S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood, 2003, 102, 1340-1346.
135. Bahlmann, F.H., DeGroot, K., Spandau, J.M., Landry, A.L., Hertel, B., Duckert, T., Boehm, S.M., Menne, J., Haller, H., Fliser, D. Erythropoietin regulates endothelial progenitor cells. Blood, 2004, 103, 921-926.
136. Assmus, B., Schachinger, V., Teupe, C., Britten, M., Lehmann, R., Dobert, N., Grunwald, F., Aicher, A., Urbich, C., Martin, H., Hoelzer, D., Dimmeler, S., Zeiher, A.M. Transplantation of Progenitor Cells And Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation, 2002, 106 (24), 3009-3017.
137. Rui, T., Feng, Q., Lei, M., Peng, T., Zhang, J., Xu, M., Dale Abel, E., Xenocostas, A., Kvietys, P.R. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc. Res., 2005, 65 (3), 719-727.
138. Ifudu, O. Patient characteristics determining rHuEPO dose requirements. Nephrol. Dial. Transplant., 2002, 17(Suppl. 5), 38-41.
139. Macdougal, I.C. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol. Dial. Transplant., 1995, 10(5), 607-614.
140. Renal Association. Adult Section 7: Anemia in patients with chronic renal failure. Treatment of adults and children with renal failure: Standards and audit measures. 3rd edition, London, Royal College of Physicians, 2002.
141. Sexton, J., Vincent, M. Managing anaemia in renal failure. Pharmaceutical. J., 2004, 273, 603-605.
142. Drueke, T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol. Dial. Transplant., 2001, 16(7), 25-28.
143. Tong, E.M., Nissenson, A.R. Erythropoietin and anemia. Semin. Nephrol., 2001, 21(2), 190-203.
144. Macdougall, I.C. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol. Dial. Transplant., 1999, 14(8), 1836-1841.
145. Drueke, T.B. R-HuEPO hyporesponsiveness-who and why? Nephrol. Dial. Transplant., 1995, 10(2), 62-68.
146. Tarng, D.C., Huang, T.P., Chen, T.W., Yang, W.C. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int. Suppl., 1999, 69, S107-S118.
147. Casadevall, N. Cellular mechanism of resistance to erythropoietin. Nephrol. Dial. Transplant., 1995, 10(6), 27-30.
148. Macdougal, I.C., Cooper, A.C. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol. Dial. Transplant., 2002, 17(11), 39-43.
149. Macdougal, I.C., Cooper, A. The inflammatory response and epoetin sensitivity. Nephrol. Dial. Transplant., 2002, 17(1), 48-52.
150. Stenvinkel, P., Barany, P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. Nephrol. Dial. Transplant., 2002, 17(5), 32-37.
151. Drueke, T.B., Eckardt, K.U. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol. Dial. Transplant., 2002, 17(5), 28-31.
152. Gallieni, M., Corsi, C., Brancaccio, D. Hyperparathyroidism and anemia in renal failure. Am. J. Nephrol., 2000, 20(2), 89-96.
153. Horl, W.H. Adjunctive therapy in anaemia management. Nephrol. Dial. Transplant., 2002, 17(5), 56-59.
154. Hurot, J.M., Cucherat, M., Haugh, M., Fouque, D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J. Am. Soc. Nephrol., 2002, 13(3), 708-714.
155. Tarng, D.C., Chang, J.G., Huang, T.P. Resistance to recombinant erythropoietin in a hemodialysis patient with heterozygous hemoglobinopathy J-Meinung. Am. J. Kidney Dis., 1997, 29(5), 769-772.
156. Walter, J. Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patientd? Nephrol. Dial. Transplant., 1993, 8, 1428.
157. Erturk, S., Ates, K., Duman, N., Karatan, O., Erbay, B., Ertug, E. Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: possible implications of angiotensin converting enzyme inhibitors. Nephrol. Dial. Transplant., 1996, 11, 396-397.
158. Mrug, M., Stopka, T., Julian, B.A., Prchal, J.F., Prchal, J.T. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J. Clin. Invest., 1997, 100, 2310-2314.
159. Vaziri, N.D. Mechanism of erythropoietin-induced hypertension. Am. J. Kidney Dis., 1999, 33(5), 821-828.
160. Maschio, G. Erythropoietin and systemic hypertension. Nephrol. Dial. Transplant., 1995, 10(2), 74-79.
161. Langenfeld, M.R.W., Veelken, R., Schobel, H.P., Friedrich, A., Schmieder, R.E. Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension? Nephrol. Dial. Transplant., 1997, 12, 1155-1160.
162. Frei, U., Nonnast-Daniel, B., Schaffer, J., Koch, K.M. Adverse cardiovascular effects of partial correction of renal anemia by recombinant human erythropoietin. Contrib. Nephrol., 1990, 82, 72-78.
163. Nowicki, M. Erythropoietin and hypertension. J. Hum. Hypertens., 1995, 9(2), 81-88.
164. Vaziri, N.D. Cardiovascular effects of erythropoietin and anemia correction. Curr. Opin. Nephrol. Hypertens., 2001, 10(5), 633-637.
165. Beccari, M. Seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention. Int. J. Artif. Organs, 1994, 17(1), 5-13.
166. Singbartl, G. Adverse events of erytthropoietin in long-term and in acute/short-term treatment. Clin. Invest., 1994, 72(6), S36-43.
167. Casserly, L.F., Dember, L.M. Thrombosis in end-stage renal disease. Semin. Dial., 2003, 16(3), 245-256.
168. Sowade, B., Sowade, O., Mocks, J., Franke,W., Warnke, H. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int. J. Mol. Med., 1998, 1(2), 303-314.
169. Bokemeyer, C., Aapro, M.S., Courdi A., Foubert, J., Link, H., Oesterborg, A., Repetto, L., Soubeyran, P. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur. J. Cancer, 2004, 40, 2201-2216.
170. Simon, T.L. Induced erythrocythemia and athletic performance. Semin. Hematol., 1994, 31(2), 128-133.
171. Bennett, C.L., Luminari, S., Nissenson, A.R., Tallman, M.S., Klinge, S.A., McWilliams, N., McKoy, J.M., Kim, B., Lyons, E.A., Trifilio, S.M., Raisch, D.W., Evens, A.M., Kuzel, T.M., Schumock, G.T., Belknap, S.M., Locatelli, F., Rossert, J., Casadevall, N. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med., 2004, 351, 1403-1408.
172. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol. Dial. Transplant., 2002, 17(Suppl 5), 42-47.
173. Eckardt, K-U., Casadevall, N. Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol. Dial. Transplant., 2003, 18, 865-869.
174. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J-J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I, Varet, B., Mayeux, P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med., 2002, 346, 469-475.
175. Locatelli, F., Del Vecchio, L. Pure red cell aplasia secondary to treatment with erythropoietin. J. Nephrol., 2003, 16(4), 461-466.
176. Locatelli, F., Del Vecchio, L. Pure red cell aplasia secondary to treatment with erythropoietin. Artif. Organs, 2003, 27(9), 755-758.
177. Macdougall, I.C. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr. Med. Res. Opin., 2004, 20(4), 576.
178. Watson, A.J. Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin. Nephrol., 1989, 9(1), 30-34.
179. Binley, K., Askham, Z., Iqball, S., Spearman, H., Martin, L., de Alwis, M., Thrasher, A.J., Ali, R.R., Maxwell, P.H., Kingsman, S., Naylor, S. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood, 2002, 100, 2406-2413.
180. Lippin, Y., Dranitzki-Elhalel, M., Brill-Almon, E., Mei-Zahav, C., Mizrachi, S., Liberman, Y., Iaina, A., Kaplan, E., Podjarny, E., Zeira, E., Harati, M., Casadevall, N., Shani, N., Galun, E. Human erythropoietin gene therapy for patients with chronic renal failure. Blood, 2005, DOI 10.1182/blood-2004-11-4174.